– USA, TX – Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to its Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc.
“We are pleased to welcome an executive with Jim’s extensive senior leadership experience to our Board of Directors,” said Tom Farrell, President and Chief Executive Officer of Bellicum. “His expertise in global marketing and commercial development, including the launch of many important therapeutics, particularly in oncology, will be invaluable as we continue to advance our pipeline of T cell immunotherapies.”
Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015, where he was instrumental in commercializing and driving product growth of Jakafi— the first drug approved by the U.S. FDA for patients with a certain chronic type of bone marrow disease. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier at Amgen, he also served as Vice President and General Manager of the Oncology Business Unit, and led his team to the successful launch of many products, including Aranesp, Neulasta, Vectibix, Nplate, Xgeva and Prolia.
Earlier in his career, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair.
Mr. Daly earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, and CAR T and TCR cell therapies.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
